In 2016 Dutch cancer patients were treated with medicines of which the active substance came from a rejected Chinese factory, where there was a serious risk of products being contaminated, Zembla reports based on its own research.
mitomycin
In 2016 Dutch cancer patients were treated with medicines of which the active substance came from a rejected Chinese factory, where there was a serious risk of products being contaminated, Zembla reports based on its own research.
